Welcome to International Society for Vaccines
User account menu
Show — User account menu
Hide — User account menu
Log in
Sign Here
Login
Remember me
Remember password
Greetings: Create an account
Main navigation
Show — Main navigation
Hide — Main navigation
Home
ABOUT ISV
ISV Constitution
ISV History
ISV Fellows
Officers & Board
Congress
Newsletter
Resources
Paper of the Year
Paper of the Month
Vaccine Books
Membership
Become An ISV Member
Existing Member Login
Main navigation
Show — Main navigation
Hide — Main navigation
Home
ABOUT ISV
ISV Constitution
ISV History
ISV Fellows
Officers & Board
Congress
Newsletter
Resources
Paper of the Year
Paper of the Month
Vaccine Books
Membership
Become An ISV Member
Existing Member Login
Skip to main content
ISV - The International Society for Vaccines
Breadcrumb
ISV Home
The Paper of month
The Paper of month
Date (field_date3)
And
December, 2013
Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model
November, 2013
Immune clearance of highly pathogenic SIV infection
October, 2013
Microbiome, sex hormones, and immune responses in the reproductive tract: Challenges for vaccine development against sexually transmitted infections
September, 2013
Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial
August, 2013
Epitope engineering and molecular metrics of immunogenicAXity: A computational approach to VLP-based vaccine design
July, 2013
A brief history of the global effort to develop a preventive HIV vaccine
June, 2013
Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza
May, 2013
A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine
April, 2013
Boost Interval Matters: A Randomized Phase I Study to Identify the Minimum Interval to Observe the H5DNA Influenza Vaccine Priming Effect
March, 2013
Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults
February, 2013
Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis
January, 2013
DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge